#Canada #Aurora Cannabis #Edmonton #Internode Pharma #HAP Pharma

Aurora Cannabis Expands Presence in UK Medical Market

In a significant move to enhance its operations in the global medical cannabis sector, Aurora Cannabis Inc. has successfully acquired Internode Pharma Limited and HAP Pharma Limited. This acquisition marks a crucial step in solidifying the company’s distribution capabilities within the burgeoning UK medical cannabis market.

Strategic Acquisition

Aurora, a Canadian leader in the medical cannabis sphere, has consistently aimed to expand its reach and offerings across the globe. With the acquisition of Internode Pharma and HAP Pharma, which are both licensed operators in the UK, Aurora is poised to streamline its supply chain and improve patient access to high-quality cannabis products.

Miguel Martin, Aurora’s CEO, emphasized the strategic importance of this acquisition, stating that it represents a milestone in the company’s objectives to lead in the international medical cannabis arena. He noted, “By investing purposefully in this market, we aim to leverage our expertise to enhance our market share and ensure a consistent supply of medical cannabis to patients in the UK.”

Growth in the UK Market

The acquisition comes at a time when the UK is experiencing increasing demand for medical cannabis. With a population of about 70 million, the UK represents one of Europe’s largest markets for cannabis-based treatments. By owning the import and distribution channels directly, Aurora will have better control over the delivery of its products, allowing for improved efficiency and reliability in meeting patient needs.

Internode Pharma operates a licensed import and distribution facility, while HAP Pharma functions as a virtual pharmacy in Birmingham, both facilitating a smoother supply chain from cultivation to patient delivery. This enables Aurora to maintain a high level of quality and compliance with regulatory standards.

Anticipated Benefits

Aurora anticipates that this strategic acquisition will positively impact its adjusted EBITDA in forthcoming quarters. By reducing reliance on third parties for distribution, the company expects to realize operational efficiencies, thereby optimizing its service delivery to patients.

Moreover, Aurora is committed to exploring additional investments that can further bolster its presence and capacity in the UK market, ensuring that it is well-equipped to meet the growing needs of UK patients.

About Aurora Cannabis

Founded with a focus on improving the lives of patients, Aurora has continually expanded its horizons beyond Canada, targeting key international markets in Europe, Australia, and New Zealand. The company boasts a robust portfolio of trusted brands, including Aurora®, MedReleaf®, Pedanios®, and several others, alongside state-of-the-art production facilities certified under Good Manufacturing Practices (GMP) in both Canada and Germany.

Aurora operates with the mission of 'Opening the World to Cannabis,' and remains dedicated to delivering high-quality cannabis products to both medical and consumer markets. As the landscape of the medical cannabis industry evolves, Aurora's strategic initiatives position it for sustained growth and leadership in the sector.

For additional information, please visit Aurora’s website and follow the company on social media platforms for ongoing updates.